Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01055106 · ClinicalTrials.gov registry record · Phase 2

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

A Phase 2 study, sponsored by Graceway Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
255
Enrollment target

NCT01055106: Completed Phase 2 study, sponsored by Graceway Pharmaceuticals.

NCT01055106 is a Phase 2 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 255 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01055106, a Phase 2 study, has completed, sponsored by Graceway Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
255 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the efficacy and safety of GW05 administered in 3 regimens versus metronidazole 0.75% for the treatment of bacterial vaginosis.

Interventions

  • DRUG Metronidazole
  • DRUG GW05

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2010-01
Est. Completion 2010-04
Phase Phase 2
Graceway Pharmaceuticals

17 total trials

What the finished NCT01055106 record still lists

NCT01055106 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher).

The record links to 0 conditions, and to 2 interventions - of which Metronidazole is the first listed.

NCT01055106 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01055106 about?

NCT01055106 is a clinical study titled "Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis". The objective of this study is to evaluate the efficacy and safety of GW05 administered in 3 regimens versus metronidazole 0.75% for the treatment of bacterial vaginosis.

What is the current status of trial NCT01055106?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2010-01. Estimated completion is 2010-04.

What interventions are being tested in trial NCT01055106?

The interventions under investigation include: Metronidazole (DRUG), GW05 (DRUG).

Who is sponsoring clinical trial NCT01055106?

This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01055106's enrollment target sits among peer trials

255 218th of 2000 higher than 1,782 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04623424 · 255 participants

    Intestinal Microbiota in Stem Cell Transplant Transplant Admission

  • NCT05114798 · 255 participants · NA

    Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

  • NCT05336188 · 255 participants · Phase 2

    Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder

  • NCT05486637 · 255 participants · Early Phase 1

    Vocal Emotion Communication With Cochlear Implants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01055106, the US trial registry maintained by the National Library of Medicine. NCT01055106 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.